FDA Clears Whitehawk Therapeutics' IND Application for HWK-007
I'm PortAI, I can summarize articles.
Whitehawk Therapeutics Inc. has received FDA clearance for its IND application for HWK-007, a PTK7-targeted antibody-drug conjugate. The company also submitted an IND for HWK-016, a MUC16-targeted ADC, with a Phase 1 trial expected to start recruiting this quarter. These milestones allow Whitehawk to advance its ADC programs into clinical trials, with initial data anticipated in early 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments